RLYB Rallybio Corporation
Mergers ·
Rallybio's board declared an estimated $13.56 per share special cash distribution on October 25, 2026. Payment is conditioned on stockholder approval at a November 4, 2026 meeting, with closing expected November 6, 2026.
Rallybio's holders would keep 2.8% of the merged company, while Avenzo's holders would own 56.6% and investors in a $215.0 million financing 40.6%. Rallybio stockholders vote on the deal on November 4.
Rallybio said Jonathan Lieber will move to part-time employment on September 15, 2026 and remain Chief Financial Officer. His employment ends at the closing of the pending Avenzo Therapeutics merger.
Candid terminated its merger agreement with Rallybio on May 3, 2026, and entered into a Permitted Alternative Agreement with UCB S.A. Rallybio intends to withdraw its Form S-4 registration statement.
Rallybio moved its listing to the Nasdaq Capital Market on August 29, 2025 after missing its first bid-price deadline. It received 180 more days, to February 23, 2026, to bring its stock back to at least $1.00.
Recursion issued 1,457,952 of its shares to Rallybio's selling subsidiary. Rallybio could receive more shares, development milestone payments and low single digit royalties later.
Rallybio sold its 50% interest in the ENPP1 joint venture to a Recursion subsidiary on July 8, 2025. It received 1,457,952 Recursion shares for an initial $7,500,000, and it could receive $12,500,000 more in stock if milestones are met.
Rallybio cut its at-the-market stock program from $100,000,000 to $9,550,000 on March 13, 2025. The company says it has sold no shares under the agreement, and the cut follows an SEC rule that limits sales for companies with a public float below $75.0 million.
Rallybio's closing bid price was below $1.00 for 30 consecutive business days. It may be eligible for another 180-day period if it applies to move its listing to the Nasdaq Capital Market.
Rallybio Corporation is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases. Its lead program, RLYB116, is a once-weekly, small volume, subcutaneously injected inhibitor of complement component 5 (C5), intended for diseases of complement dysregulation. The company says it completed two Phase 1 trials in healthy participants and a confirmatory Phase 1 trial in 2025. RLYB332, a long-acting matriptase-2 antibody for diseases of iron overload, is in preclinical development. The text names paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, refractory generalized myasthenia gravis and neuromyelitis optica spectrum disorder as complement-related diseases with remaining need. On March 1, 2026, Rallybio entered into a merger agreement with Candid, a clinical-stage company advancing T-cell engager therapeutics for autoimmune diseases. A concurrent financing with an aggregate commitment of approximately $505.5 million is part of the transaction, and Rallybio's pre-merger assets, called Legacy Assets, are subject to a contingent value right. The company also cites a membership interest purchase agreement with Recursion Pharmaceuticals, Inc. dated July 8, 2025.
| Product or program | What it is | Stage |
|---|---|---|
| RLYB116 | Once-weekly subcutaneous C5 inhibitor for complement dysregulation diseases | two Phase 1 trials completed; confirmatory Phase 1 completed in 2025 |
| RLYB332 | Long-acting matriptase-2 antibody for diseases of iron overload | preclinical development |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $858,000 | $636,000 |
| Research and development | $19.6 million | $41.5 million |
| Net income (loss) | -$9.0 million | -$57.8 million |
| Cash from operations | -$29.8 million | -$49.3 million |
| Cash and equivalents | $31.4 million | $13.9 million |
| Short-term investments | $23.4 million | $51.6 million |
Our latest story on this, dated Oct 15, 2026: "Rallybio holders to own 2.8% of the combined company in Avenzo reverse merger". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 13, 2025: "Rallybio cuts at-the-market stock program to $9,550,000 from $100,000,000". The story links the filing or release it is based on. Read the story.
Rallybio Corporation trades under the ticker RLYB on NASDAQ.
Rallybio Corporation is listed on NASDAQ.
The SEC Central Index Key (CIK) for Rallybio Corporation is 1739410. Its filings are on SEC EDGAR.
5,310,499 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Rallybio Corporation under United States.
Our directory classifies Rallybio Corporation as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Rallybio Corporation is US75120L2097.
aibio.space lists Rallybio Corporation among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Rallybio Corporation is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases. Its lead program, RLYB116, is a once-weekly, small volume, subcutaneously injected inhibitor of complement component 5 (C5), intended for diseases of complement dysregulation.
RLYB116: Once-weekly subcutaneous C5 inhibitor for complement dysregulation diseases Stage: two Phase 1 trials completed; confirmatory Phase 1 completed in 2025.
RLYB332: Long-acting matriptase-2 antibody for diseases of iron overload Stage: preclinical development.
$858,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a merger or acquisition agreement. SEC Form S-4. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,5.01,5.02,7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio